254 related articles for article (PubMed ID: 31370270)
1. Immune Resistance and EGFR Antagonists in Colorectal Cancer.
Giordano G; Remo A; Porras A; Pancione M
Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31370270
[No Abstract] [Full Text] [Related]
2. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.
Zhou J; Ji Q; Li Q
J Exp Clin Cancer Res; 2021 Oct; 40(1):328. PubMed ID: 34663410
[TBL] [Abstract][Full Text] [Related]
3. Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy.
Kasper S; Reis H; Ziegler S; Nothdurft S; Mueller A; Goetz M; Wiesweg M; Phasue J; Ting S; Wieczorek S; Even A; Worm K; Pogorzelski M; Breitenbuecher S; Meiler J; Paul A; Trarbach T; Schmid KW; Breitenbuecher F; Schuler M
Oncotarget; 2017 Jul; 8(28):45898-45917. PubMed ID: 28507280
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of resistance to anti-EGFR therapy in colorectal cancer.
Zhao B; Wang L; Qiu H; Zhang M; Sun L; Peng P; Yu Q; Yuan X
Oncotarget; 2017 Jan; 8(3):3980-4000. PubMed ID: 28002810
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow.
Pohl M; Schmiegel W
Dig Dis; 2016; 34(5):574-9. PubMed ID: 27332557
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence.
Troiani T; Napolitano S; Della Corte CM; Martini G; Martinelli E; Morgillo F; Ciardiello F
ESMO Open; 2016; 1(5):e000088. PubMed ID: 27843640
[TBL] [Abstract][Full Text] [Related]
7. Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer.
Jeong WJ; Cha PH; Choi KY
World J Gastroenterol; 2014 Aug; 20(29):9862-71. PubMed ID: 25110417
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS.
Liu J; Hu J; Cheng L; Ren W; Yang M; Liu B; Xie L; Qian X
Onco Targets Ther; 2016; 9():557-65. PubMed ID: 26869800
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.
Chan DLH; Segelov E; Wong RS; Smith A; Herbertson RA; Li BT; Tebbutt N; Price T; Pavlakis N
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007047. PubMed ID: 28654140
[TBL] [Abstract][Full Text] [Related]
10. Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer.
Nakamura Y; Yoshino T
Oncologist; 2018 Nov; 23(11):1310-1318. PubMed ID: 29700206
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.
Pietrantonio F; Vernieri C; Siravegna G; Mennitto A; Berenato R; Perrone F; Gloghini A; Tamborini E; Lonardi S; Morano F; Picciani B; Busico A; Volpi CC; Martinetti A; Battaglin F; Bossi I; Pellegrinelli A; Milione M; Cremolini C; Di Bartolomeo M; Bardelli A; de Braud F
Clin Cancer Res; 2017 May; 23(10):2414-2422. PubMed ID: 27780856
[No Abstract] [Full Text] [Related]
12. Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer.
Kocoglu H; Velibeyoglu FM; Karaca M; Tural D
World J Gastrointest Oncol; 2016 Jan; 8(1):1-7. PubMed ID: 26798432
[TBL] [Abstract][Full Text] [Related]
13. RAS Amplification as a Negative Predictor of Benefit from Anti-EGFR-Containing Therapy Regimens in Metastatic Colorectal Cancer.
Schrock AB; Lee JK; Sandhu J; Madison R; Cho-Phan C; Snider JW; Castellanos E; Venstrom JM; Fakih M
Oncologist; 2021 Jun; 26(6):469-475. PubMed ID: 33465286
[TBL] [Abstract][Full Text] [Related]
14. Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer.
Dienstmann R; Salazar R; Tabernero J
Am Soc Clin Oncol Educ Book; 2015; ():e149-56. PubMed ID: 25993166
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity in primary colorectal cancer and its corresponding metastases: a potential reason of EGFR-targeted therapy failure?
Li Z; Jin K; Lan H; Teng L
Hepatogastroenterology; 2011; 58(106):411-6. PubMed ID: 21661405
[TBL] [Abstract][Full Text] [Related]
16. Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives.
Martinelli E; Ciardiello D; Martini G; Troiani T; Cardone C; Vitiello PP; Normanno N; Rachiglio AM; Maiello E; Latiano T; De Vita F; Ciardiello F
Ann Oncol; 2020 Jan; 31(1):30-40. PubMed ID: 31912793
[TBL] [Abstract][Full Text] [Related]
17. Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib.
De Pauw I; Lardon F; Van den Bossche J; Baysal H; Pauwels P; Peeters M; Vermorken JB; Wouters A
Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30650638
[TBL] [Abstract][Full Text] [Related]
18. Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer.
Lee MS; Kopetz S
Clin Colorectal Cancer; 2015 Dec; 14(4):203-18. PubMed ID: 26077270
[TBL] [Abstract][Full Text] [Related]
19. Acquired resistance to EGFR-targeted therapies in colorectal cancer.
Van Emburgh BO; Sartore-Bianchi A; Di Nicolantonio F; Siena S; Bardelli A
Mol Oncol; 2014 Sep; 8(6):1084-94. PubMed ID: 24913799
[TBL] [Abstract][Full Text] [Related]
20. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
